Somatic TP53 mutations in the era of genome sequencing
P Hainaut, GP Pfeifer - Cold Spring …, 2016 - perspectivesinmedicine.cshlp.org
Amid the complexity of genetic alterations in human cancer, TP53 mutation appears as an
almost invariant component, representing by far the most frequent genetic alteration overall …
almost invariant component, representing by far the most frequent genetic alteration overall …
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
M Canale, K Andrikou, I Priano, P Cravero, L Pasini… - Cancers, 2022 - mdpi.com
Simple Summary Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-
related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) …
related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) …
Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
SY Liu, H Bao, Q Wang, WM Mao, Y Chen… - Nature …, 2021 - nature.com
The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over
chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell …
chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell …
[HTML][HTML] Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
L La Fleur, E Falk-Sörqvist, P Smeds, A Berglund… - Lung cancer, 2019 - Elsevier
Objectives Non-small cell lung cancer (NSCLC) is a heterogeneous disease with unique
combinations of somatic molecular alterations in individual patients, as well as significant …
combinations of somatic molecular alterations in individual patients, as well as significant …
The role of DNA repair pathways in cisplatin resistant lung cancer
S O'Grady, SP Finn, S Cuffe, DJ Richard… - Cancer treatment …, 2014 - Elsevier
Platinum chemotherapeutic agents such as cisplatin are currently used in the treatment of
various malignancies such as lung cancer. However, their efficacy is significantly hindered …
various malignancies such as lung cancer. However, their efficacy is significantly hindered …
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non–Small …
Purpose Our previous work evaluated individual prognostic and predictive roles of TP53,
KRAS, and EGFR in non–small-cell lung cancer (NSCLC). In this analysis, we explore the …
KRAS, and EGFR in non–small-cell lung cancer (NSCLC). In this analysis, we explore the …
Postoperative adjuvant systemic therapy in completely resected non–small-cell lung cancer: a systematic review
P Bradbury, D Sivajohanathan, A Chan, S Kulkarni… - Clinical lung cancer, 2017 - Elsevier
The purpose of the present review was to determine whether the use of postoperative
adjuvant systemic therapy in patients with completely resected non–small-cell lung cancer …
adjuvant systemic therapy in patients with completely resected non–small-cell lung cancer …
TP53 co-mutations in advanced EGFR-mutated non–small cell lung cancer: Prognosis and therapeutic strategy for cancer therapy
S Liu, J Yu, H Zhang, J Liu - Frontiers in oncology, 2022 - frontiersin.org
Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …
Ex Vivo Explant Cultures of Non–Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy
E Karekla, WJ Liao, B Sharp, J Pugh, H Reid… - Cancer research, 2017 - AACR
To improve treatment outcomes in non–small cell lung cancer (NSCLC), preclinical models
that can better predict individual patient response to novel therapies are urgently needed …
that can better predict individual patient response to novel therapies are urgently needed …
TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis
J Gu, Y Zhou, L Huang, W Ou… - Molecular and …, 2016 - spandidos-publications.com
A number of studies have examined the association between tumor protein 53 (TP53)
mutations and the clinical outcome in patients with non-small-cell lung cancer (NSCLC) …
mutations and the clinical outcome in patients with non-small-cell lung cancer (NSCLC) …